Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
Clinical trial NCT06100276 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06100276
- Sponsor
- UniQure Biopharma B.V.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-01
- Primary completion
- 2026-09-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.